Page 1

Q3 Interim Report Third quarter of 2021 Summary of financial performance Net sales for the quarter totaled SEK 38 thousand ( 701 ) . Sales for the quarter comprised revenue related to Dosell sales . Operating income for the quarter totaled SEK -5,342 thousand ( 7,255 ) . The comparative period included the non - recurring effect from the sale of iZafe AB . Excluding the sale of iZafe , operating profit for the comparative period amounted to SEK -6,745 thousand . Income after financial items for the quarter was SEK - 6,183 thousand ( 7,103 ) . Excluding the sale of iZafe , income after financial items for the comparative period amounted to SEK -6,897 thousand . Cash flow for the period was SEK -6,475 thousand ( 8,818 ) . The positive cash flow for the comparative period was due to the proceeds received from the divestment of iZafe AB . Earnings per share for the quarter , basic and diluted , were SEK -0.2 ( 0.2 ) . Equity per share at the end of the period was SEK 1.5 ( 1.1 ) . The equity ratio at the end of the period was 62.3 percent ( 87.4 ) . Important events in the quarter ¡ Zafe decided to carry out a fully guaranteed rights issue of units amounting to approximately SEK 53 million . The rights issue is fully guaranteed . iZafe Group held a general meeting of the shareholders , resulting in a supplementary general meeting at which a majority of shareholders requested an alternative Board of Directors , which was voted through . The consumer pilot project has been successfully completed , with the consumer version of the Dosell medication - dispensing robot found to be safe and easy to use . Following the development of the consumer version of Dosell in Sweden , this version will also be launched in Italy in 2021 . Important events since the end of the quarter The consumer version of Dosell is being launched in Sweden on apoteket.se . Dosell is now available for everyone who regularly takes medication and wants to avoid medication errors through better medication management and treatment compliance to prevent harm . ¡ Zafe Group has signed an agreement with Apoteket AB to introduce Dosell on the Swedish consumer market , exclusively through Apoteket AB's channels . The agreement with Apoteket , and its unique market position as one of the leading suppliers of medication sachets on the Swedish market , creates a direct market of the more than 200,000 people who currently take medication using medication sachets from suppliers such as Apoteket . The company is leading the development of digital dispensing of medication through its medication - dispensing robot Dosell , which reduces the risk of medication errors at home , relieves the burden on healthcare systems , improves quality of life for patients and creates a safer environment for family . The final outcome of the rights issue of units , consisting of shares and series TO10 B share warrants , has been published . The rights issue has been fully subscribed , with approximately 43.6 percent subscribed for using unit rights , around 4.1 percent without the use of unit rights and approximately 52.3 percent subscribed for by issue guarantors . iZafe Group AB has been listed on Nasdaq First North Premier Growth Market since 2018 . Deputy Chairman Göran Hermansson and CEO Anders Segerström together subscribed for a further 458,000 units in the ongoing rights issue of units , in addition to the initial subscription . iZafe Group has finalized most of its PCT patent application for the Dosell medication - dispensing robot in order to prepare for the international expansion , planned to be carried out after the ongoing rights issue . Patent applications have been made in those key markets where iZafe has identified significant demand for Dosell . About iZafe Group iZafe Group is a life sciences company conducting research , development and marketing of digital medical solutions and services for safer medication management at home . Hepro AS has last issued a final approval of the new version of Dosell and has officially approved the pharmaceutical robot in its entirety for the Norwegian market . iZafe's customers comprise both consumers and public and private sector care providers in Sweden , the Nordic region and worldwide . iZafe Group primarily sells through well - established partners that already have close , long - term customer relationships with prioritized customer groups . The Group is headquartered in Stockholm , Sweden . Fund iZafe iZafe Group AB ( publ . ) Corporate ID number : 556762-3391 www.izafe.se | info@izafegroup.com | +46 ( 0 ) 8-21 11 21